Latest Anemia News
New study "adds to the evidence of obesity-associated advantages," researchers conclude.
In a small study, intermittent vs continuous administration of IV iron resulted in less hemoglobin variability in hemodialysis patients with anemia.
Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.
Patients with vs without anemia prior to starting hemodialysis (HD) were more likely to die despite achieving target hemoglobin levels at month 4 after HD initiation.
Anemia control may be one more reason to treat elevated parathyroid hormone levels.
Anemia is 66% and 84% more likely to develop among patients in the 3rd and 4th quartiles of serum fibroblast growth factor 23 level vs those in the 1st quartile.
Retacrit is biosimilar to the drugs Epogen and Procrit.
In a study, increases in red blood cell distribution width during the first year of dialysis was associated with greater risks for death.
Patients' mean hemoglobin levels stayed relatively stable after converting from an erythropoiesis-stimulating agent to the investigational drug.
New study shows that IV iron repletion with sodium ferric gluconate complex increased platelet count significantly at week 3 post-infusion and non-significantly at week 4.
Clinicians should advise women who could become pregnant to use effective contraception before and after taking the anemia drug.
In a study, use of anticoagulants was associated with 85% fewer atherosclerotic events.
In a trial, oral calcitriol of 0.5 mcg daily did not reduce hepcidin levels in patients with stage 3 to 4 CKD.
Dialysis patients receiving more or less than 200 mg per month of IV iron had similar risks of death, infection, cardiovascular disease, and hospitalization, meta-analysis shows.
The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer